Brentuximab Vedotin and Chemotherapy Effective in Peripheral T-cell Lymphoma Brentuximab Vedotin and Chemotherapy Effective in Peripheral T-cell Lymphoma

Brentuximab vedotin (Adcetris, Seattle Genetics) in combination with chemotherapy is significantly more effective than chemotherapy alone in patients with CD30-positive peripheral T-cell lymphomas, according to the multinational phase 3 ECHELON-2 trial.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news